Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Core Insights - Genmab has made significant progress in the first eight months of 2025, particularly with its late-stage programs EPKINLY and Rina-S, showcasing promising data and product profiles [3][4]. Group 1: Product Development - The company is excited about the emerging target product profiles for its late-stage programs, especially Rina-S, which has shown strong proof-of-concept data in second-line endometrial cancer and platinum-resistant ovarian cancer [3]. - Rina-S is demonstrating a compelling product profile across various dimensions, including activity at different expression levels, response rates, duration of response, and safety [4]. - There is a clear line of sight to potential registrational data for Rina-S moving into 2026, indicating strong future prospects for the product [4].